Advertisement

CCN Proteins pp 523-532 | Cite as

Method for Analysis of Matrix Degradation by CCN2 Through the MMP/TIMP System

  • Susan V. McLennan
  • Danqing Min
  • Xiaoyu Wang
  • Stephen M. TwiggEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1489)

Abstract

Many studies have shown effects of members of the CCN family on matrix synthesis and accumulation but few have examined degradative pathways. This scarcity of information is in part due to the lack of suitable model systems. Here we describe methods for making rhCCN2 and also for the preparation of a biosynthetically labeled matrix substrate that can be used to measure the effect of CCN on cellular or secreted degradative pathways.

Key words

CCN2 Connective tissue growth factor Matrix metalloproteinase Tissue inhibitor of matrix metalloproteinase Matrix degradation pathways 

Notes

Acknowledgements

The work described in this chapter was supported by NH&MRC and Rebecca L Cooper Medical Research Foundation grants, to Professor Stephen Twigg and Associate Professor Susan McLennan.

References

  1. 1.
    Ayo SH, Radnik RA, Garoni JA et al (1990) High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am J Pathol 136:1339–1348, Erratum (1990) 137:preceding 225PubMedPubMedCentralGoogle Scholar
  2. 2.
    Abdel Wahab N, Mason RM (1996) Modulation of neutral protease expression in human mesangial cells by hyperglycaemic culture. Biochem J 320:777–783CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    McLennan SV, Yue DK, Turtle JR (1998) Effect of glucose on matrix metalloproteinase activity in mesangial cells. Nephron 79:293–298CrossRefPubMedGoogle Scholar
  4. 4.
    Kim HS, Nagalla SR, Oh Y et al (1997) Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc Natl Acad Sci U S A 94:12981–12986CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Twigg SM, Joly AH, Chen MM et al (2002) Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology 143:1260–1269CrossRefPubMedGoogle Scholar
  6. 6.
    McLennan SV, Wang XY, Moreno V et al (2004) Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 145(12):5646–5655CrossRefPubMedGoogle Scholar
  7. 7.
    Wang X, McLennan SV, Twigg SM (2011) CCN-2 is up-regulated by and mediates effects of matrix bound advanced glycated end-products in human renal mesangial cells. J Cell Commun Signal 5(3):193–200. doi: 10.1007/s12079-011-0137 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    He TC, Zhou S, Costa LTD et al (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95:2509–2514CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yang DH, Kim HS, Wilson EM et al (1998) Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments in human biological fluids, and up-regulation of IGFBP-rP2 expression by TGF-β in Hs578T human breast cancer cells. J Clin Endocrinol Metab 83:2593–2596PubMedGoogle Scholar
  10. 10.
    McLennan SV, Fisher EJ, Yue DK et al (1994) High glucose concentration causes a decrease in mesangium degradation: a factor in the pathogenesis of diabetic nephropathy. Diabetes 43:1041–1045CrossRefPubMedGoogle Scholar
  11. 11.
    Twigg SM, Cao Z, McLennan SV et al (2002) Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143:4907–4915CrossRefPubMedGoogle Scholar
  12. 12.
    Min D, Lyons JG, Jia J et al (2006) 2-Methoxy-2,4-diphenyl-3(2H)-furanone-labeled gelatin zymography and reverse zymography: a rapid real-time method for quantification of matrix metalloproteinases-2 and -9 and tissue inhibitors of metalloproteinases. Electrophoresis 27(2):357–364CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Susan V. McLennan
    • 1
    • 2
  • Danqing Min
    • 1
    • 2
  • Xiaoyu Wang
    • 1
  • Stephen M. Twigg
    • 1
    • 2
    Email author
  1. 1.Greg Brown Diabetes and Endocrinology Research Laboratory, Sydney Medical School, Charles Perkins CentreThe University of SydneySydneyAustralia
  2. 2.Department of EndocrinologyRoyal Prince Alfred HospitalCamperdownAustralia

Personalised recommendations